Northwest Biotherapeutics, Inc.
NWBO
$0.207
-$0.003-1.43%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -74.47M | -78.62M | -75.20M | -67.54M | -76.92M |
| Total Depreciation and Amortization | 1.96M | 1.93M | 1.84M | 1.73M | 1.69M |
| Total Amortization of Deferred Charges | 1.98M | 2.16M | 2.40M | 2.37M | 2.67M |
| Total Other Non-Cash Items | 13.84M | 15.82M | 16.53M | 13.49M | 22.30M |
| Change in Net Operating Assets | 2.90M | -767.00K | -362.00K | -3.70M | 4.73M |
| Cash from Operations | -53.79M | -59.48M | -54.80M | -53.64M | -45.53M |
| Capital Expenditure | -1.35M | -1.62M | -2.34M | -3.44M | -5.18M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.35M | -1.62M | -2.34M | -3.44M | -5.18M |
| Total Debt Issued | 32.56M | 39.30M | 30.45M | 33.35M | 25.27M |
| Total Debt Repaid | -1.23M | -426.00K | -284.00K | -385.00K | -309.00K |
| Issuance of Common Stock | 11.65M | 4.54M | 2.78M | 1.72M | 2.72M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 11.63M | 16.51M | 14.57M | 13.33M | 17.66M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 643.00K | 843.00K | 4.75M | 4.75M | 4.36M |
| Cash from Financing | 55.26M | 60.76M | 52.26M | 52.76M | 49.69M |
| Foreign Exchange rate Adjustments | -3.27M | 1.79M | 1.17M | -523.00K | -2.32M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.16M | 1.46M | -3.71M | -4.84M | -3.33M |
